Poland· PL-100513740
Nemluvio
A nemolizumab product containing nemolizumab, registered in Poland by Galderma International. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nemolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Nemolizumab · ATC D11AH12
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nemolizumab costs, country by country.
Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nemolizumab · price per daily dose (0.8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$67.16
The record
At a glance
URPL (Poland)- Active substance
- Nemolizumab
- Manufacturer
- Galderma International
- Country
- Poland (PL)
- ATC code
- D11AH12
- ATC class
- Nemolizumab
- Defined daily dose
- 0.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin03499320017039
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nemolizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenNemluvio 30 mg Pulver och vätska till injektionsvätska, lösning i förfylld injektionspennaGalderma International
- IcelandNemluvioGalderma International
- BelgiumNemluvio 30 mgGalderma International
- United KingdomNemluvio 30mg powder and solvent for solution for injection pre-filled pensGalderma (UK) Ltd
- NorwayNemluvioGalderma International
- SwitzerlandNemluvio 30 mg, Pulver und Lösungsmittel für Injektionslösung im FertigpenGalderma SA
- SpainNEMLUVIO 30 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE EN PLUMA PRECARGADAGalderma International
- CzechiaNEMLUVIOGalderma International, La Défense
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nemluvio
- Liechtenstein · Nemluvio
- Norway · Nemluvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4a41ae0a-8f8e-453d-922a-7f33644999f3 GET /v1/drugs/4a41ae0a-8f8e-453d-922a-7f33644999f3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "30 mg",
"packaging": "Rpz ¦ EU/1/24/1901/001 ¦ 160578\n1 wstrzykiwacz 0,49 ml\n¦ UR/Z/4c/169/26 - 03499320017039\nRpz ¦ EU/1/24/1901/002 ¦ 160579\n2 wstrzykiwacze 0,49 ml\nRpz ¦ EU/1/24/1901/003 ¦ 160580\n3 wstrzykiwacze 0,49 ml",
"substance": "Nemolizumab 30 mg",
"common_name": "Nemolizumab",
"pl_product_id": "100513740",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nemolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.